Janux Therapeutics (JANX) Research & Development (2020 - 2026)

Janux Therapeutics (JANX) has reported Research & Development for 7 consecutive years, with $26.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 7.02% year-over-year to $26.8 million; the TTM figure through Mar 2026 stood at $127.7 million (up 60.83% YoY), while the FY2025 annual figure was $125.9 million, up 84.09% from the prior year.
• Research & Development fell to $26.8 million in Q1 2026 per JANX's latest filing, from $31.5 million in the prior quarter.
• Across five years, Research & Development topped out at $34.7 million in Q2 2025 and bottomed at $10.2 million in Q1 2022.
• Historically, Research & Development has averaged $19.4 million across 5 years, with a median of $15.4 million in 2022.
• Annual changes were most pronounced in 2022 — Research & Development soared 429.04% — and 2023, when it declined 20.69%.
• Janux Therapeutics' Research & Development stood at $15.4 million in 2022, then slipped by 20.69% to $12.2 million in 2023, then surged by 69.97% to $20.8 million in 2024, then surged by 51.63% to $31.5 million in 2025, then fell by 15.01% to $26.8 million in 2026.
• Business Quant data shows JANX's Research & Development at $26.8 million in Q1 2026, $31.5 million in Q4 2025, and $34.6 million in Q3 2025.